Pakinax Limited is a biotechnology company focused on the discovery and development of innovative anti-cancer therapeutics and cancer vaccines, with a particular emphasis on pancreatic cancer. The company targets key signalling pathways involved in tumour progression and metastasis, particularly in aggressive, treatment-resistant malignancies. By combining precision oncology with advanced platforms such as small-molecule kinase inhibitors and next-generation vaccine technologies, Pakinax aims to develop more effective and targeted therapies. Currently at the early preclinical stage, the company is advancing a pipeline of novel candidates toward clinical development. Pakinax’s mission is to translate cutting-edge research into transformative treatments that improve survival and outcomes for patients with pancreatic cancer and other hard-to-treat cancers.